Login to Your Account



Guilford Mulls Dosing Plan For Phase III With Aquavan

By Randall Osborne


Monday, March 28, 2005
Guilford Pharmaceuticals Inc. on Thursday said adjustments in its voluntarily suspended Phase III study with Aquavan may extend only "modestly" the time to filing a new drug application, but Wall Street proved unforgiving, as investors took away more than 33 percent of the stock's value. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription